SCHEMBL9704263

SCHEMBL9704263

Cc1ccc2nn(-c3ccc(N(C)C)cc3)nc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 12/20 0.57
NPC1 O15118 12/20 0.57
ALDH1A1 P00352 9/20 0.57
MEN1 O00255 9/20 0.57
KMT2A Q03164 9/20 0.57
KDM4E B2RXH2 8/20 0.57
MAPT P10636 8/20 0.57
SMN1; SMN2 Q16637 5/20 0.57
HPGD P15428 4/20 0.57
GAA P10253 3/20 0.57
TP53 P04637 2/20 0.57
CASP1 P29466 2/20 0.57
CASP7 P55210 2/20 0.57
HSD17B10 Q99714 2/20 0.57
ALOX5 P09917 1/20 0.51
MCL1 Q07820 1/20 0.49
TSHR P16473 1/20 0.45
LMNA P02545 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3221922 0.86 NPC1 (0.73) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL3422262 0.83 NPC1 (0.53) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL3033496 0.82 ALOX5 (0.50) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL13290970 0.82 NPC1 (0.55) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL3041535 0.82 ALOX5 (0.50) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL3042432 0.82 NPC1 (0.55) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL3042867 0.82 NPC1 (0.55) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL13290986 0.82 ALOX5 (0.50) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL3032584 0.82 NPC1 (0.69) RAB9ANPC1ALDH1A1MEN1KMT2A
SCHEMBL3048501 0.82 ALOX5 (0.50) RAB9ANPC1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100150833-A1 COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES MOLECULAR NEUROIMAGING, LLC 2010-06-17 US disclosed
US-20100143251-A1 COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES MOLECULAR NEUROIMAGING, LLC 2010-06-10 US disclosed
EP-0476519-A1 Photopolymerisable composition and recording material produced therefrom MORTON INTERNATIONAL, INC. (US) 1992-03-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100150833-A1 COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES APP, BACE1, BACE2 RAB9A 4657/4885NPC1 160/4885ALDH1A1 1882/4885
US-20100143251-A1 COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES APP, BACE1, BACE2 RAB9A 4657/4885NPC1 160/4885ALDH1A1 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.